Dr. Boobalan Pachaiyappan
Recent Articles about Capricor Therapeutics Inc.
Biotech Battles FDA, Target Price Shows Potential 90% Gains 10/01/2025
Capricor Therapeutics Inc. (CAPR:NASDAQ) has recently been involved in a "tug-of-war with the FDA." Read on to see why one Roth analyst still rates this stock as a Buy.
© 2025 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
